A Phase 3, Multiregional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants With Relapsed/Refractory Primary Central Nervous System Lymphoma (IGNITE)
OPEN TO ACCRUAL
III
NCT07104032
TOllila@BrownHealth.org
